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 Abstract: A new, simple, precise, accurate and reproducible RP-HPLC method for Simultaneous 
estimation of Desloratadine and Montelukast in bulk and pharmaceutical formulations. Separation of 
Desloratadine and Montelukast was successfully achieved on a ECLEPSE XDB C8 (4.6 x 150mm, 5 
m, Make: Waters) or equivalent in an isocratic mode utilizing K2HPO4 buffer (pH: 8.6)
 
Methanol 
(60:40%v/v) at a flow rate of 0.8 mL/min and elute was monitored at 261 nm, with a retention time 
of 2.485 and 3.800 minutes for Desloratadine and Montelukast. The method was validated and the 
response was found to be linear in the drug concentration range of 50 µg/mL to 150 µg/mL for 
Desloratadine and 50 µg/mL to 150 µg/mL for Montelukast. The LOD and LOQ for Desloratadine were 
found to be 2.759, 9.195 respectivly. The LOD and LOQ for Montelukast were found to be 2.9091, 
9.6970 respectively. This method was found to be good percentage recovery for Desloratadine and 
Montelukast were found to be 100.00% and 100.00% respectively indicates that the proposed method is 
highly accurate. The specificity of the method shows good correlation between retention times of 
standard with the sample so, the method specifically determines the analyte in the sample without 
interference from excipients of tablet dosage forms. The method was extensively validated according to 
ICH guidelines for Linearity, Range, Accuacy, Precesion, Specificity and Robustness. 
Keywords: RP-HPLC; Desloratadine, Montelukast. 
I. INTRODUCTION 
Desloratadine: 13-chloro-2-(piperidin-4-ylidene)-4 
azatricyclo [9.4.0.0^{3,8}] pentadeca 
1(11),3,5,7,12,14-hexaene. It belongs to the 
benzocycloheptapyridines. These are aromatic 
compounds containing a benzene ring and a 
pyridine ring fused to a seven membered 
carbocycle. Desloratadine is a second generation, 
tricyclic antihistamine that which has a selective 
and peripheral H1-antagonist action. 
 
Figure1: Chemical structure Of Desloratadine 
Montelukast: 2-[1-({[(1R)-1-{3-[(E)-2-(7-
chloroquinolin-2-yl) ethenyl] phenyl}-3-[2-(2-
hydroxypropan-2-yl) phenyl] propyl] sulfanyl} 
methyl) cyclopropyl] acetic acid. Montelukast 
inhibits the actions of LTD4 at the CysLT1 receptor, 
preventing airway edema, smooth muscle 
contraction, and enhanced secretion of thick, 
viscous mucus. It is an Antilipidemic Agents 
Figure2: Chemical structure of Montelukast 
II. MATERIALS AND METHOD 
A. Instrumentation  
The separation was carried out on HPLC 
system with Waters 2695 alliance with 
binary HPLC pump, Waters 2998 PDA 
detector, Waters Empower2 software with 
Eclipse XBD-C8, (150mm × 4.6 ; 5µm) 
column. 
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B. Chemicals and Reagents  
Desloratadine and Montelukast was a gift 
sample by Dr. Reddy’s Laboratories Ltd., 
Hyderabad. K2HPO4, Methanol of HPLC 
grade was purchased from E. Merck (India) 
Ltd., Mumbai. Ortho phosphoric acid of AR 
grade was obtained from S.D. Fine 
Chemicals Ltd., Mumbai and mille Q water. 
C. HPLC Conditions 
The mobile phase consisting of K2HPO4 
buffer (pH: 8.6)
 
Methanol was degassed and 
were pumped from the solvent reservoir in 
the ratio of 60:40v/v was pumped into the 
column at a flow rate of 0.8 ml/min. The 
column temperature was 40°C. The 
detection was monitored at 261nm and the 
run time was 6min. The volume of injection 
loop was 10µl prior to injection of the drug 
solution the column was equilibrated for at 
least 15 min. with the mobile phase flowing 
through the system. 
D. Preparation of standard solution 
Accurately weigh and transfer 5mg of 
Desloratadine and 10mg of Montelukast into 
50ml of volumetric flask and add 10ml of 
methanol to each and sonicate 10min (or) 
shake 5min and makeup the volume with 
methanol. Pipette out 5.0ml standard stock 
standard stock into 25ml volumetric flask 
dilute to volume with methanol and inject 
into HPLC. 
E. Preparation Of Sample Solution 
Accurately weighed 797.6mg of sample. 
Transfer the sample powder into 50ml of 
volumetric flask add 10ml methanol, 
sonicate for 20mins. Then make up the 
volume with methanol and filter through the 
0.45µm filter paper. Transfer 5ml of above 
solution 25 ml volumetric flask and make up 
the volume with methanol. 
 
Figure 3: Standard chromatogram for 
Desloratadine and Montelukast 
 
 
Figure 4: Formulation chromatogram for 
Desloratadine and Montelukast 
F. Method validation 
1. System Suitability Studies  
The column efficiency, resolution and 
peak asymmetry were calculated for the 
standard solutions (Table I).The values 
obtained demonstrated the suitability of 
the system for the analysis of this drug 
combinations, system suitability 
parameters may fall within ± 3 % 
standard deviation range during routine 
performance of the method. 
TABLE I: SYSTEM SUITABILITY PARAMETERS 
Parameter  Desloratadine Montelukast 
Retention 
time 
2.485 3.800 
Theoretical 
plates 
5123 5986 
Tailing factor 1.39 1.52 
% RSD 0.4 0.3 
2.  Specificity 
Specificity is the ability to assess 
unequivocally the analyte in the 
presence of components which may 
expect to be present. Typically these 
might include impurities, degradants, 
matrix, etc. 
3. Accuracy and precision 
The accuracy of the method was 
determined by recovery experiments. 
The recovery studies were carried out 
six times. The percentage recovery and 
standard deviation of the percentage 
recovery were calculated. From the data 
obtained, added recoveries of standard 
drugs were found to be accurate (Table-
II&III). 
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TABLE II: ACCURACY FOR DESLORATADINE 
S.
No 
Accur
acy 
level 
Sam
ple 
weig
ht 
μg/
ml 
adde
d 
μg/
ml 
fou
nd 
% 
Recov
ery 
% 
Me
an 
 
 
 
1 
 
 
 
50% 
398.
80 
39.6
40 
39.7
8 
100  
 
 
100 
398.
80 
39.6
40 
39.7
9 
100 
398.
80 
39.6
40 
39.7
6 
100 
398.
80 
39.6
40 
39.7
7 
100 
398.
80 
39.6
40 
39.8
0 
100 
398.
80 
39.6
40 
39.7
5 
100 
 
 
2 
 
 
100% 
797.
60 
79.2
80 
79.3
6 
100  
100 
797.
60 
79.2
80 
79.4
3 
100 
797.
60 
79.2
80 
79.3
6 
100 
 
 
 
3 
 
 
 
150% 
1196
.40 
118.
920 
119.
03 
100  
 
100 1196
.40 
118.
920 
118.
90 
100 
1196
.40 
118.
920 
119.
01 
100 
1196
.40 
118.
920 
118.
95 
100 
1196
.40 
118.
920 
118.
98 
100 
1196
.40 
118.
920 
118.
98 
100 
TABLE III: ACCURACY FOR MONTELUKAST 
S.
No 
Accur
acy 
level 
Sam
ple 
weig
ht 
μg/m
l 
adde
d 
μg/
ml 
fou
nd 
% 
Recov
ery 
% 
Me
an 
 
 
 
1 
 
 
 
50% 
398.
80 
79.7
60 
79.8
3 
100  
 
100 398.
80 
79.7
60 
79.7
9 
100 
398.
80 
79.7
60 
79.8
9 
100 
398.
80 
79.7
60 
79.7
7 
100 
398.
80 
79.7
60 
79.8
5 
100 
398.
80 
79.7
60 
79.8
4 
100 
 
 
2 
 
100% 
797.
60 
159.
20 
159.
34 
100  
100 
797.
60 
159.
20 
159.
47 
100 
797.
60 
159.
20 
159.
56 
100 
 
 
 
3 
 
 
 
150% 
1196
.40 
239.
280 
239.
28 
100  
 
100 1196
.40 
239.
280 
239.
24 
100 
1196
.40 
239.
280 
239.
47 
100 
1196
.40 
239.
280 
239.
49 
100 
1196
.40 
239.
280 
239.
37 
100 
1196
.40 
239.
280 
239.
29 
100 
 
Figure 5: AccuracyChromatograms-50%of 
Desloratadine and Montelukast 
Figure 6: AccuracyChromatograms-100%of 
Desloratadine and Montelukast 
 
Figure 7: AccuracyChromatograms-150%of 
Desloratadine and Montelukast 
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The precision of the method was demonstrated by 
inter-day and intra-day variation studies. In the 
intraday studies, six repeated injections of standard 
and sample solutions were made and the response 
factor of drug peaks and percentage RSD were 
calculated. In the inter-day variation studies. six 
repeated injections of standard and sample 
solutions were made for three consecutive days and 
response factor of drugs peaks and percentage RSD 
were calculated. The chromatograms of three 
different levels shown in Figure 5, 6 &7. From the 
data obtained, the developed RP-HPLC method 
was found to be precise. (Table-IV) 
TABLE IV: PRECISION STUDIES 
 
4. Linearity and range 
The linearity of the method was 
determined at five concentration levels. 
The calibration curve was constructed 
by plotting response factor against 
concentration of drugs. The slope and 
intercept value for calibration curve was 
Y=43363X (R
2
=0.999) for desloratidine 
and Y=49489X (R
2
=1) for montelukast. 
The results shows that an excellent 
correlation exists between areas and 
concentration of drugs within the 
concentration range indicated above.  
The overlay chromatograms of 
Linearity for Desloratadine and 
Montelukast shows in Figure 10 and the 
results for calibration curves are given 
in Figure 8&9. 
         
Figure 8: Linearity Curve for Desloratidine 
Figure 9: Linearity Curve for Montelukast 
 
Figure 10:  Overlay chromatograms of Linearity 
for Desloratidine and Montelukast 
5. Robustness 
Robustness of the method was 
determined by making slight changes in 
the chromatographic conditions.    It 
was observed that there were no marked 
changes in the chromatograms which 
demonstrated that the RPHPLC method 
developed, are robust (Table-V&VI). 
TABLE V: ROBUSTNESS FOR DESLORATIDINE 
S.No Area Area %Assay 
(Des ) 
%Assay 
(Des) (mon) (mon ) 
1 4678289 4945121 99 100 
2 4677549 4941492 99 100 
3 4676508 4945109 99 100 
4 4675202 4943465 99 100 
5 4677862 4942694 99 100 
6 4678822 4949517 99 100 
S.No 
Sample 
Name RT Area 
USP 
Tailing 
1 Temp-1 4.955 4960210 1.39 
2 Temp-2 2.978 4927514 1.35 
3 Flow-1 3.725 4511175 1.32 
   4 Flow-2 3.722 4512813 1.32 
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TABLE VI: ROBUSTNESS FOR MONTELUKAST 
6. LOD&LOQ 
Limit of quantification and detection 
were predicted by plotting linearity 
curve for different nominal 
concentrations of Desloratadine and 
Montelukast. RSD (σ) method was 
applied; the LOQ and LOD values were 
predicted using following formulas (a) 
and (b). Precision was established at 
these predicted level 
(a) LOQ = 10 σ / S 
(b) LOD = 3.3 σ / S 
Where  
σ = residual standard deviation of 
response  
S = slope of the calibration curve. 
Figure 11: Chromatograms for LOQ 
Figure 12: Chromatograms for LOD 
TABLE VII: LOD and LOQ for Desloratidine and 
Montelukast 
 
 
III. RESULTS AND DISCUSSION 
System suitability results were given by table1 and 
system suitability parameters are retention time, 
resolution, tailing and plate count were shown 
uniformity and %RSD was less than 1. So we can 
say system is suitable for analysis method 
specificity was concluded by figure:3 and figure:4 
those figures are Desloratadine and  montelukast 
standard chromatogram and other one is 
formulation they were not observed placebo and 
excipients peaks interference with standard and 
analytic peak so it proves method is selective. The 
result given in table I say that the method precision 
passed for both Desloratadine and montelukast 
studies. The method accuracy was evaluated by 
recovery studies. Desloratadine and  montelukast 
recovery was founded 99%&100% as per ICH 
97%- 103% and also percentage RSD was very low 
so method is accurate shown in table II&III. 
Linearity calibration curve was given below fig: 
8&9 and plot the graph three different 
concentrations versus areas to construct the linear 
regression equation and to calculate the value of 
correlation co-efficient. Linear correlation was 
found to be Y=43363X for Desloratidine and y = 
49488X for Montelukast Method robustness results 
were given by table V&VI, LOQ and LOD Results 
were given by table VII. 
IV. CONCLUSION 
The proposed HPLC method was found to be 
simple, precise, accurate and sensitive for the 
simultaneous estimation of    Desloratidine and 
Montelukast pharmaceutical dosage forms. Hence, 
this method can easily and conveniently adopt for 
rountine quality control analysis of    Desloratidine 
and Montelukast pure and its pharmaceutical 
dosage forms. 
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